You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 11,191,908

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,191,908 protect, and when does it expire?

Patent 11,191,908 protects ZURNAI (AUTOINJECTOR) and XYOSTED (AUTOINJECTOR) and is included in two NDAs.

This patent has eleven patent family members in five countries.

Summary for Patent: 11,191,908

Patent landscape, scope, and claims:

Title:	Syringe shock absorber for use in an injection device
Abstract:	An injection device, for example, an auto-injector of any type, includes a sleeve configured to hold a medicament chamber. The sleeve may be sufficiently deformable such that it functions as a shock absorbing member to distribute the force exerted on the medicament chamber during use of the injection device.
Inventor(s):	Mehawej; John Pierre (Robbinsdale, MN), Travanty; Michael (Wayzata, MN)
Assignee:	Antares Pharma, Inc. (Ewing, NJ)
Application Number:	15/503,077
Patent Claim Types: see list of patent claims	Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 11,191,908

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Purdue Pharma Lp	ZURNAI (AUTOINJECTOR)	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	218590-001	Aug 7, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-001	Sep 28, 2018		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-002	Sep 28, 2018		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-003	Sep 28, 2018		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 11,191,908

PCT Information
PCT Filed	August 07, 2015	PCT Application Number:	PCT/US2015/044271
PCT Publication Date:	February 18, 2016	PCT Publication Number:	WO2016/025327

International Family Members for US Patent 11,191,908

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2957679	⤷ Subscribe
European Patent Office	3177346	⤷ Subscribe
European Patent Office	3984572	⤷ Subscribe
Spain	2886553	⤷ Subscribe
Japan	2017523858	⤷ Subscribe
Japan	2019150661	⤷ Subscribe
Japan	2021104369	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.